Bayer raises 2026 adjusted EBITDA outlook to EUR 9.8 billion-10.3 billion at constant currencies

Bitget2026/11/03 09:13

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Bayer raised its 2026 constant-currency adjusted EBITDA forecast to 9.8 billion–10.3 billion euros, from 9.6 billion–10.1 billion euros.
Free cash flow is now forecast at negative 1.5 billion–negative 0.5 billion euros, an improvement of 1 billion euros.
Year-end net financial debt is projected at 28 billion–29 billion euros at constant currencies, versus 29 billion–30 billion euros previously.
The pharmaceutical adjusted EBITDA margin outlook increased to 25%–27% from 24%–26%, supported by strong performance.
Nine-month adjusted EBITDA grew 7%, while organic sales rose 3%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bayer AG published the original content used to generate this news brief on November 03, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Bayer raises 2026 adjusted EBITDA outlook to EUR 9.8 billion-10.3 billion at constant currencies

You may also like

Crypto prices